← ANALYST RATINGS · TIPRANKS
Zura Bio (ZURA): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $19.75, the highest $26.00, the lowest $11.00. The average is +409.0% from the last price of $3.88.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.50 → $4.00−11.1% | Hold | +3.1% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.50 → $4.00−11.1% | Hold | +3.1% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.50 → $4.00−11.1% | Hold | +3.1% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | −9.8% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $26.00 | Buy | +570.1% | Reiterated | 07.10.26on TipRanks 07:25 | +5.5%next day −0.5% · 5 days +6.7% | ↗ |
| Unknown Analyst | Leerink Partners | $11.00 | Buy | +183.5% | Reiterated | 02.10.26on TipRanks Oct 5 04:05 | −1.5%next day −5.1% · 5 days −3.8% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $20.00 | Buy | +415.5% | Reiterated | 02.10.26on TipRanks Oct 5 04:05 | −1.5%next day −5.1% · 5 days −3.8% | ↗ |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.50 → $4.00−11.1% | Hold | +3.1% | Reiterated | 24.09.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.50 → $4.00−11.1% | Hold | +3.1% | Reiterated | 24.09.26on TipRanks 03:05 | — | |
| Martin Fan★★★★★★★★★★#177 · hits 87% · avg +94.8% | Wedbush | $22.00 | Buy | +467.0% | Reiterated | 12.08.26on TipRanks 09:56 | +3.7%next day −3.3% · 5 days +1.5% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 11.08.26on TipRanks 16:05 | +3.7%next day −3.3% · 5 days +1.5% | ↗ |
| Justin Kim★★★★★★★★★★#1624 · hits 50% · avg +13.9% | Oppenheimer | $16.00 | Buy | +312.4% | Reiterated | 08.06.26on TipRanks Jun 11 13:45 | +3.6%next day +4.8% · 5 days +2.1% | ↗ |
| Daniil Gataulin★★★★★★★★★★#2392 · hits 39% · avg +14.9% | Chardan Capital | $4.89 → $11.00+124.9% | Buy | +183.5% | Reiterated | 07.05.26on TipRanks 18:30 | +4.7%next day −1.1% · 5 days −1.7% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $18.00 | Buy | +363.9% | Reiterated | 01.12.25on TipRanks Dec 2 09:10 | −2.7%next day −5.8% · 5 days +0.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Zura Bio
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.67 at a price of $4.16 (+444.9%); now: $19.75 at $3.88 (+409.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 5 | 3 | 5 |
| Buy | 0 | 0 | 1 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.20 (from $-0.24 to $-0.14). Last quarter: $-0.21.
Best top-analyst consensus in the sector · Healthcare
About Zura Bio
- CEO: Sandeep C. Kulkarni
- Employees: 40
- 1489 W. Warm Springs Road, Henderson, NV, 89014, US
- zurabio.com
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Data from the stock’s TipRanks forecast page, read 104 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗